Facebook
X
LinkedIn
ForwardGeorge Du Toit
Biography:
Dr George Du Toit
George du Toit is Professor of Paediatric Allergy, King’s College London and Evelina London Children’s Hospital, Guy's and St Thomas' NHS Foundation Trust.
George is active in clinical research where his major focus has been the prevention and treatment of food allergy. George is Senior Senior Investigator on the NIH-funded LEAP-Trio study (aimed at assessing the long term allergy outcomes of a peanut intervention in high risk infants), Co-PI of the EAT-On Study (aimed at assessing the long term allergy and health outcomes of a 6 food intervention in the EAT Study) and CI (UK) on numerous Peanut Allergy Desensitisation trials.
George is the lead clinician for the NHS Children’s Drug Allergy service at Evelina London Children’s Hospital and past Chairperson of the European Academy of Allergy and Clinical Immunology (EAACI) Paediatric Section.
COI
- GdT reports grants from National Institute of Allergy and Infectious Diseases (NIAID, NIH), Food Allergy & Research Education (FARE), MRC & Asthma UK Centre, Action Medical Research and National Peanut Board.
- Scientific Advisory Board member Aimmune and Novartis
- Investigator on pharma-sponsored allergy studies (Aimmune, and DBV Technologies).
Financial relationships
-
Type of financial relationship:There are no financial relationships to disclose.Date added:03/01/2022Date updated:03/01/2022
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.